Transcatheter Aortic Valve Implantation in Mixed Aortic Valve Disease: A Multicenter Study.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 09 2023
Historique:
received: 04 03 2023
revised: 06 07 2023
accepted: 13 07 2023
medline: 28 8 2023
pubmed: 31 7 2023
entrez: 30 7 2023
Statut: ppublish

Résumé

Mixed aortic valve disease (MAVD), defined by the concurrent presence of aortic stenosis (AS) and insufficiency is frequently seen in patients who have undergone transcatheter aortic valve implantation (TAVI). However, studies comparing the outcomes of TAVI in MAVD versus isolated AS have demonstrated conflicting results. Therefore, we aim to assess the outcomes of TAVI in patients with MAVD in comparison with those with isolated severe AS. Patients who underwent native valve TAVI for severe AS at 3 tertiary care academic centers between January 2012 and December 2020 were included and categorized into 3 groups based on concomitant aortic insufficiency (AI) as follows: group 1, no AI; group 2, mild AI; and group 3, moderate to severe AI. Outcomes of interest included all-cause mortality and all-cause readmission rates at 30 days and 1 year. Other outcomes include bleeding, stroke, vascular complications, and the incidence of paravalvular leak at 30 days after the procedure. Of the 1,588 patients who underwent TAVI during the study period, 775 patients (49%) had isolated AS, 606 (38%) had mild AI, and 207 (13%) had moderate to severe AI. Society of Thoracic Surgeons risk scores were significantly different among the 3 groups (5% in group 1, 5.5% in group 2, and 6% in group 3, p = 0.003). Balloon-expandable valves were used in about 2/3 of the population. No statistically significant differences in 30-day or 1-year all-cause mortality and all-cause readmission rates were noted among the 3 groups. Post-TAVI paravalvular leak at follow-up was significantly lower in group 1 (2.3%) and group 2 (2%) compared with group 3 (5.6%) (p = 0.01). In summary, TAVI in MAVD is associated with comparable outcomes at 1 year compared with patients with isolated severe AS.

Identifiants

pubmed: 37517135
pii: S0002-9149(23)00601-X
doi: 10.1016/j.amjcard.2023.07.064
pii:
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

394-402

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Dr. Goldsweig reports consulting with Inari and speaker fees from Edwards and Philips. The remaining authors have no competing interests to declare.

Auteurs

Raviteja R Guddeti (RR)

Division of Cardiovascular Diseases, Creighton University School of Medicine, Omaha, Nebraska.

Gauravpal S Gill (GS)

Division of Cardiovascular Diseases, Creighton University School of Medicine, Omaha, Nebraska.

Jai D Parekh (JD)

Division of Cardiovascular Diseases, University of Iowa, Iowa City, Iowa.

Aravdeep S Jhand (AS)

Division of Cardiovascular Diseases, University of Nebraska Medical Center, Omaha, Nebraska.

Ryan W Walters (RW)

Department of Clinical Research, Creighton University School of Medicine, Omaha, Nebraska.

Sidakpal S Panaich (SS)

Division of Cardiovascular Diseases, University of Iowa, Iowa City, Iowa.

Andrew M Goldsweig (AM)

Division of Cardiovascular Diseases, University of Nebraska Medical Center, Omaha, Nebraska.

Venkata Mahesh Alla (VM)

Division of Cardiovascular Diseases, Creighton University School of Medicine, Omaha, Nebraska. Electronic address: venkataalla@creighton.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH